INS and obesity disorder: The use of a small‐molecule inhibitor of PKD2 as well as PKD1 and PKD3 (CRT0066101), also allowed a localized inhibition of this pathway in the small intestine, thereby decreasing intestinal lipid absorption to ameliorate obesity and restore insulin sensitivity.